Epstein–Barr virus-associated diseases are important global health concerns. As a group I
carcinogen, EBV accounts for 1.5% of human malignances, including both epithelial-and …

Background Population screening of asymptomatic persons with Epstein–Barr virus (EBV)
DNA or antibodies has improved the diagnosis of nasopharyngeal carcinoma and survival …

Over the last few years, certain areas in the management nasopharyngeal carcinoma (NPC)
that have an impact on the care of these patients have evolved, particularly with regard to …

Epstein–Barr virus (EBV) infection is ubiquitous worldwide and is associated with multiple
cancers, including nasopharyngeal carcinoma (NPC). The importance of EBV viral genomic …

A meeting of experts was held in November 2021 to review and discuss available data on
performance of Epstein-Barr virus (EBV)–based approaches to screen for early stage …

Epstein–Barr virus (EBV) is an oncogenic virus infecting more than 95% of the world's
population. After primary infection—responsible for infectious mononucleosis in young …

Nasopharyngeal carcinoma (NPC) is a squamous carcinoma with apparent geographical
and racial distribution, mostly prevalent in East and Southeast Asia, particularly …

The vacuolar protein sorting 33B (VPS33B) was rarely reported in malignant tumors. In this
research, we demonstrated that overexpression of VPS33B inhibited proliferation and …

PURPOSE Screening for nasopharyngeal carcinoma (NPC) has shown an improvement in
early detection and survival rates of NPC in endemic regions. It is critical to evaluate whether …

Epstein‐Barr virus (EBV) infection is prevalent in global population and associated with
multiple malignancies and autoimmune diseases. During the infection, EBV‐harbored or …